DE3684578D1 - Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung. - Google Patents

Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung.

Info

Publication number
DE3684578D1
DE3684578D1 DE8686309857T DE3684578T DE3684578D1 DE 3684578 D1 DE3684578 D1 DE 3684578D1 DE 8686309857 T DE8686309857 T DE 8686309857T DE 3684578 T DE3684578 T DE 3684578T DE 3684578 D1 DE3684578 D1 DE 3684578D1
Authority
DE
Germany
Prior art keywords
prostatatum
human
original
methods
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686309857T
Other languages
English (en)
Inventor
Wright, Jr
James J Starling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EASTERN VIRGINIA MEDICAL AUTHORITY NORFOLK VA US
Eastern Virginia Medical Authority
Original Assignee
EASTERN VIRGINIA MEDICAL AUTHORITY NORFOLK VA US
Eastern Virginia Medical Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EASTERN VIRGINIA MEDICAL AUTHORITY NORFOLK VA US, Eastern Virginia Medical Authority filed Critical EASTERN VIRGINIA MEDICAL AUTHORITY NORFOLK VA US
Application granted granted Critical
Publication of DE3684578D1 publication Critical patent/DE3684578D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE8686309857T 1985-12-17 1986-12-17 Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung. Expired - Lifetime DE3684578D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80971985A 1985-12-17 1985-12-17
US94191186A 1986-12-15 1986-12-15

Publications (1)

Publication Number Publication Date
DE3684578D1 true DE3684578D1 (de) 1992-04-30

Family

ID=27123249

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686309857T Expired - Lifetime DE3684578D1 (de) 1985-12-17 1986-12-17 Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung.

Country Status (3)

Country Link
EP (1) EP0228243B1 (de)
JP (1) JP2574269B2 (de)
DE (1) DE3684578D1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690890A (en) * 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
EP0635575A1 (de) * 1993-07-22 1995-01-25 Wallac Oy Monoklonale Antikörper gegen Epitope in freiem uber nicht in Alpha-1-antichymotrypsin komplexiertem Prostata spezifisches Antigen
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
WO1995030758A1 (en) * 1994-05-10 1995-11-16 Mayo Foundation For Medical Education And Research Recombinant hk2 polypeptide
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP0974057B1 (de) * 1996-07-15 2005-09-21 Mayo Foundation For Medical Education And Research Verfahren zur detektion der hk2 polypeptide
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
EP0981541B1 (de) * 1997-03-10 2004-06-02 The Regents Of The University Of California Prostata stammzell-antigen (psca)
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
AU8259798A (en) 1997-06-20 1999-01-04 George G Klee Method for detection of breast cancer
CA2340592A1 (en) 1998-08-31 2000-03-09 Urogenesys, Inc. Phelix: a testis-specific protein expressed in cancer
US7875278B2 (en) 2005-02-18 2011-01-25 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues

Also Published As

Publication number Publication date
EP0228243B1 (de) 1992-03-25
JPS62215870A (ja) 1987-09-22
EP0228243A1 (de) 1987-07-08
JP2574269B2 (ja) 1997-01-22

Similar Documents

Publication Publication Date Title
DE3781067D1 (de) Uebertragungsaufzeichnungsmittel und ihre verwendung fuer uebertragungsaufzeichnungsverfahren.
DE3684578D1 (de) Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung.
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
NO162179C (no) Monoklonale antistoffer for anvendelse in vitro.
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
DK391785D0 (da) Monoklonale antistoffer samt deres fremstilling og anvendelse
DE3788148T2 (de) Monoklonale Antikörper und deren Verwendung.
DE3885355D1 (de) Monoklonale Antikörper.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
DE3689948T2 (de) Monoklonale antikörper und testverfahren.
DE3882727D1 (de) Mycoplasma-membran-antigene und ihre verwendung.
IL70746A0 (en) Specific cea-family antigens,antibodies specific thereto and methods for the use thereof
DE3884646T2 (de) Humanes Karcinom-assoziertes Antigen und an dieses Antigen bindende Antikörper.
DK188185A (da) Monoklonalt antistof
NO862920L (no) Onkofetale spesifikke monoklonale antistoffer, fremgangsmaate for fremstilling og anvendelse.
DE3888437D1 (de) Immobilisierte Antikörper.
DE3587714D1 (de) Menschliches alpha 2-Plasmin spezifischer monoklonaler Antikörper.
DK717888A (da) Monoklonale antistoffer
DE3780256D1 (de) Anti-pci-monoklonaler antikoerper.
DK144485D0 (da) Monoklonale antistoffer
DK37785D0 (da) Monoclonalt antistof
DE3580482D1 (de) Monoklonale antikoerper und immunisierung damit.
NO873488D0 (no) Monoklonale antistoffer.
DE3687542T2 (de) Monoklonaler antikoerper gegen humanes protein c.
NO890116D0 (no) Monoklonale antistoffer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee